Home Cart Sign in  
Chemical Structure| 4311-88-0 Chemical Structure| 4311-88-0

Structure of Necrostatin-1
CAS No.: 4311-88-0

Chemical Structure| 4311-88-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Necrostatin-1 is an inhibitor of RIP1 and can decrease TNF-α-induced necroptosis with EC50 of 490 nM.

Synonyms: Nec-1

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Necrostatin-1

CAS No. :4311-88-0
Formula : C13H13N3OS
M.W : 259.33
SMILES Code : CN1C(NC(CC2=CNC3=C2C=CC=C3)C1=O)=S
Synonyms :
Nec-1
MDL No. :MFCD00056916
InChI Key :TXUWMXQFNYDOEZ-UHFFFAOYSA-N
Pubchem ID :2828334

Safety of Necrostatin-1

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H317
Precautionary Statements:P280

Related Pathways of Necrostatin-1

pyroptosis

Isoform Comparison

Biological Activity

Description
Necrostatin-1 (Nec-1) serves as a potent inhibitor of necroptosis, capable of crossing the blood-brain barrier, with an effective concentration (EC50) of 490 nM in Jurkat cells. It specifically inhibits RIP1 kinase activity (EC50=182 nM) and also functions as an inhibitor of IDO[1].
Target
  • TNF-α

    RIP1, EC50:490 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
HEK293T cells 10 μM 12 hours Evaluation of the role of Cys191 in GSDMD-NT pore formation Nat Immunol. 2020 Jul;21(7):736-745
BMDMs 50 µM 3 h Inhibition of necroptosis, reducing hypoxia-induced cell death J Exp Med. 2021 Sep 6;218(9):e20200667.
THP-1 cells 30 µM 1 hour To evaluate the inhibitory effect of Necrostatin-1 on necroptosis in THP-1 cells. The results showed that Necrostatin-1 completely inhibited HMGB1 release, supporting the major contribution of necrotic cell death in VEXAS. Nat Commun. 2024 Jan 30;15(1):910.
astrocytes 30 μM 4 h To evaluate the effect of RIPK1 kinase activity on inflammatory gene expression in astrocytes. Results showed that Nec-1s inhibited RIPK1 kinase activity and reduced inflammatory gene expression. Cell Rep. 2021 May 11;35(6):109112.
microglia 30 μM 2 h To evaluate the effect of RIPK1 kinase activity on inflammation and cell death in microglia. Results showed that Nec-1s inhibited RIPK1 kinase activity and reduced cell death. Cell Rep. 2021 May 11;35(6):109112.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Rats Middle cerebral artery occlusion (MCAO) model Intracerebroventricular injection 20 mM Single injection, observed for 72 hours Nec-1 treatment significantly reduced ischemia-induced brain damage and neurological deficits, inhibited RIPK1 phosphorylation and its downstream signaling pathways. Aging Dis. 2019 Aug 1;10(4):807-817
Mice Experimental autoimmune encephalomyelitis (EAE) model Oral 30 mg/kg and 60 mg/kg Twice daily, continuous treatment To evaluate the therapeutic effect of RIPK1 kinase inhibitor in the EAE model. Results showed that RIPK1 kinase inhibitor significantly alleviated disease symptoms. Cell Rep. 2021 May 11;35(6):109112.
Mice Myocardial infarction model Subcutaneous injection 5 mg/kg Once daily, continued until the end of the experiment Inhibition of necroptosis, improving survival and cardiac function after myocardial infarction J Exp Med. 2021 Sep 6;218(9):e20200667.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.86mL

0.77mL

0.39mL

19.28mL

3.86mL

1.93mL

38.56mL

7.71mL

3.86mL

References

 

Historical Records

Categories